|

Rocbrutinib Clinical Trials

4 actively recruiting trials across 1 location

No change since August 2026

Also known as: LP-168

Pipeline

Phase 2: 2Phase 3: 2

Top Sponsors

  • Guangzhou Lupeng Pharmaceutical Company LTD.3
  • Newave Pharmaceutical Inc1

Indications

  • Cancer3
  • CLL Progression1
  • CLL, Relapsed1
  • CLL, Refractory1
  • Relapsing-remitting Multiple Sclerosis (RRMS)1

Other3 trials

A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 3
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
Phase 2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2

Skokie, Illinois1 trial

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Orchard Healthcare Research

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.